NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: KPL · data 2026-11-01
Kwality Pharmaceuticals Ltd
In plain words
Price: 12.0% below its 52-week high of ₹3,949.
Delivery: 43.1% of traded shares were kept for delivery over the last 10 sessions, against 43.1% over the last 60.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹554 cr |
| Net profit (last 12 months) | ₹81 cr |
| Sales growth, 3 years (yearly) | 26.1% |
| Profit growth, 3 years (yearly) | 51.5% |
At a glance
P/E 44.5, dividend yield 0.0%. Price relative to earnings and book value (low is cheaper, not better).
ROE 22.6%, ROCE 31.4%, operating margin 20.8%: how much profit it earns on the money it uses.
Debt/equity 0.39, Profit growth 51.5% and sales growth 26.1% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- High return on equity (22.6%).
- Healthy operating margin (20.8%).
- Profit grew 51.5% a year over 3 years.
None flagged by these rules.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Smart-money activity
15/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 10/30: Delivery 46.2% over the last 20 sessions vs 33.2% in the 40 before (1.39x); shares delivered per day 0.6x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Common questions
Is Kwality Pharmaceuticals Ltd debt-free?
Its latest reported debt-to-equity ratio is 0.39.
What is Kwality Pharmaceuticals Ltd's P/E ratio?
About 44.5, based on the last 12 months' earnings and a price of ₹3,475.3 (data 2026-11-01).
What is the 52-week high and low of Kwality Pharmaceuticals Ltd?
The 52-week high is ₹3,949 and the 52-week low is ₹1,561.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Kwality Pharmaceuticals Ltd | ₹3,475.3 | ₹3,604 cr | 44.5 | — | 22.6% | 31.4% | 0.39 | +98.9% |
| Zota Health Care Ltd. | ₹1,328.8 | ₹4,031 cr | — | 7.4 | -16.1% | -9.7% | 0.39 | -15.4% |
| Aarti Drugs Limited | ₹435.2 | ₹3,977 cr | 20.8 | — | 13.4% | 13.2% | 0.37 | -12.1% |
| Unichem Laboratories Limited | ₹483.75 | ₹3,404 cr | 11.2 | — | 9.8% | -0.5% | 0.18 | +3.4% |
| Shukra Pharmaceuticals Ltd. | ₹74.87 | ₹3,295 cr | 96.6 | — | 28.9% | 31.3% | 0.06 | +78.1% |
| Ind-Swift Laboratories Ltd. | ₹368.2 | ₹3,195 cr | 38.2 | 2.2 | 3.4% | -0.2% | 0.01 | +260.3% |
Compare KPL with ZOTA in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open KPL in NSE Scanner →